RxDoctor Payments Data

Michael Bunda, MD

Cardiovascular Disease · Prince George, VANPI 1912955451

Payments from drug & device makers

$3,252in general payments, 2019–2025

Across 192 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$583
  • Johnson & Johnson$315
  • Sanofi-aventis U.S. LLC$294
  • Amgen$260
  • Merck$225
  • Pfizer$207
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,13196%
  • Education$1224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,252 in reported general payments places this provider in the 60th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$8,282
Medicare patients
13
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$147,379
MultaqDronedarone Hcl14$31,974
XareltoRivaroxaban27$20,364
EntrestoSacubitril/Valsartan29$18,580
Repatha SyringeEvolocumab14$12,112
Atorvastatin Calcium283$1,941
Metoprolol Succinate139$1,666
Ezetimibe45$1,045
Rosuvastatin Calcium70$999
ClopidogrelClopidogrel Bisulfate74$698
Losartan Potassium78$531
Metoprolol Tartrate90$488
Amiodarone Hcl29$429
Flecainide Acetate19$415
Hydrochlorothiazide138$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$207$147,379183 claims
Sanofi-aventis U.S. LLCMultaq$294$31,97414 claims
Johnson & JohnsonXarelto$315$20,36427 claims
NovartisEntresto$583$18,58029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Prince George

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →